HALO vs. HROW

Last updated Apr 2, 2026

Compare and contrast key facts about Halozyme Therapeutics, Inc. (HALO) and Harrow Health, Inc. (HROW).

Performance

HALO vs. HROW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Halozyme Therapeutics, Inc. (HALO) and Harrow Health, Inc. (HROW). The values are adjusted to include any dividend payments, if applicable.

HALO vs. HROW - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
HALO Halozyme Therapeutics, Inc.	-2.82%	40.77%	29.36%	-35.04%	41.51%	-5.85%	140.89%	21.19%	-27.79%	105.06%
HROW Harrow Health, Inc.	-27.69%	46.05%	199.55%	-24.12%	70.83%	25.95%	-11.83%	36.73%	234.71%	-32.00%

Fundamentals

EPS HALO : $2.61 HROW : -$0.20
PS Ratio HALO : 5.68 HROW : 3.37
Total Revenue (TTM) HALO : $1.40B HROW : $272.30M
Gross Profit (TTM) HALO : $1.17B HROW : $204.37M
EBITDA (TTM) HALO : $590.37M HROW : $36.50M

Returns By Period

In the year-to-date period, HALO achieves a -2.82% return, which is significantly higher than HROW's -27.69% return. Over the past 10 years, HALO has underperformed HROW with an annualized return of 20.96%, while HROW has yielded a comparatively higher 24.53% annualized return.

HALO

• 1D: 1.19%
• 1M: -6.37%
• YTD: -2.82%
• 6M: -12.73%
• 1Y: 5.71%
• 3Y*: 19.64%
• 5Y*: 9.04%
• 10Y*: 20.96%

HROW

• 1D: 0.48%
• 1M: -33.89%
• YTD: -27.69%
• 6M: -26.75%
• 1Y: 41.83%
• 3Y*: 18.75%
• 5Y*: 39.16%
• 10Y*: 24.53%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HALO vs. HROW — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HALO

HALO Risk / Return Rank: 43
HALO Sharpe Ratio Rank: 45
HALO Sortino Ratio Rank: 40
HALO Omega Ratio Rank: 43
HALO Calmar Ratio Rank: 42
HALO Martin Ratio Rank: 43

HROW

HROW Risk / Return Rank: 61
HROW Sharpe Ratio Rank: 63
HROW Sortino Ratio Rank: 62
HROW Omega Ratio Rank: 61
HROW Calmar Ratio Rank: 60
HROW Martin Ratio Rank: 61

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HALO vs. HROW - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Harrow Health, Inc. (HROW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HALO	HROW	Difference
Sharpe ratio Return per unit of total volatility	0.13	0.65	-0.52
Sortino ratio Return per unit of downside risk	0.47	1.28	-0.81
Omega ratio Gain probability vs. loss probability	1.08	1.17	-0.09
Calmar ratio Return relative to maximum drawdown	0.08	0.85	-0.77
Martin ratio Return relative to average drawdown	0.17	2.19	-2.02
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HALO vs. HROW - Sharpe Ratio Comparison

The current HALO Sharpe Ratio is 0.13, which is lower than the HROW Sharpe Ratio of 0.65. The chart below compares the historical Sharpe Ratios of HALO and HROW, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HALO	HROW	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.13	0.65	-0.52
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.23	0.56	-0.33
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.48	0.35	+0.14
Sharpe Ratio (All Time) Calculated using the full available price history	0.23	-0.04	+0.27

Correlation

The correlation between HALO and HROW is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HALO vs. HROW - Dividend Comparison

Neither HALO nor HROW has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

HALO vs. HROW - Drawdown Comparison

The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum HROW drawdown of -99.46%. Use the drawdown chart below to compare losses from any high point for HALO and HROW.

Drawdown Indicators

	HALO	HROW	Difference
Max Drawdown Largest peak-to-trough decline	-74.26%	-99.46%	+25.20%
Max Drawdown (1Y) Largest decline over 1 year	-31.69%	-39.27%	+7.58%
Max Drawdown (5Y) Largest decline over 5 years	-49.06%	-71.15%	+22.09%
Max Drawdown (10Y) Largest decline over 10 years	-49.06%	-71.15%	+22.09%
Current Drawdown Current decline from peak	-19.49%	-74.33%	+54.84%
Average Drawdown Average peak-to-trough decline	-32.02%	-86.86%	+54.84%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.78%	15.16%	-0.38%

Volatility

HALO vs. HROW - Volatility Comparison

The current volatility for Halozyme Therapeutics, Inc. (HALO) is 9.11%, while Harrow Health, Inc. (HROW) has a volatility of 15.62%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than HROW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HALO	HROW	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.11%	15.62%	-6.51%
Volatility (6M) Calculated over the trailing 6-month period	23.48%	52.39%	-28.91%
Volatility (1Y) Calculated over the trailing 1-year period	43.82%	64.92%	-21.10%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	39.51%	70.23%	-30.72%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	43.38%	70.70%	-27.32%

Financials

HALO vs. HROW - Profitability Comparison

The chart below illustrates the profitability comparison between Halozyme Therapeutics, Inc. and Harrow Health, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HALO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Halozyme Therapeutics, Inc. reported a gross profit of 373.00M and revenue of 451.77M. Therefore, the gross margin over that period was 82.6%.

HROW - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Harrow Health, Inc. reported a gross profit of 70.62M and revenue of 89.09M. Therefore, the gross margin over that period was 79.3%.

HALO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Halozyme Therapeutics, Inc. reported an operating income of -92.89M and revenue of 451.77M, resulting in an operating margin of -20.6%.

HROW - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Harrow Health, Inc. reported an operating income of 15.59M and revenue of 89.09M, resulting in an operating margin of 17.5%.

HALO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Halozyme Therapeutics, Inc. reported a net income of -141.59M and revenue of 451.77M, resulting in a net margin of -31.3%.

HROW - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Harrow Health, Inc. reported a net income of 6.63M and revenue of 89.09M, resulting in a net margin of 7.4%.